Significance of liver metastasis volume in breast cancer patients treated with stereotactic body radiotherapy

2021 ◽  
Author(s):  
Ezgi Oymak ◽  
Ozan Cem Guler ◽  
Cem Onal
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
Stereotactic Body Radiotherapy ◽  
Breast Cancer Patients

Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1105-1105
Author(s):  
W. Han ◽  
H. Kim ◽  
J. Lee ◽  
K. Lee ◽  
H. Moon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Lung Metastasis ◽  
Stage Iii ◽  
Breast Cancer Patients ◽  
Metastatic Lesions ◽  
Treatment Plans

1105 Background: Preoperative clinical staging in breast cancer patients is important to determine the most appropriate treatment plans and to predict prognosis for individual patients. Identifying unexpected distant metastases in newly diagnosed breast cancer patients frequently alters initial treatment plans. Routine imaging studies to detect lung or liver metastasis is not indicated in patients with early and operable breast cancer. A recent study showed that routine use of chest radiograph and liver ultrasound does not provide much diagnostic benefit in early breast cancer patients. Methods: We aimed to investigate the value of preoperative computed tomography to detect asymptomatic liver and lung metastasis in breast cancer patients. We performed preoperative CT for 667 breast cancer patients to detect lung and liver metastasis among 1,636 primary breast cancer patients who had been diagnosed and treated between January 2006 and December 2007 at Seoul National University Hospital. Results: CT showed abnormal findings (suspicious of metastasis or indeterminate nodules) in 78 patients (10.5%). Among these, abnormal finding in 13 patients (1.7%) turned out to be true metastatic lesions. There was no CT-detected lung or liver metastasis in patients with T1 tumor and 4 metastases in patients with T2 tumor. There was no CT-detected lung or liver metastasis in patients with negative axillary lymph node metastasis. When patients were classified according to the AJCC staging, CT-detected true metastatic lesions were only present in stage III patients (13 out of 173 patients, 7.5%). The true metastatic lesions in lung or liver were all small sized nodules, ranging from 0.3cm to 1.2cm in largest diameters. In seven patients, the CT-detected metastatic lesions were less than 1cm which is in contrast with the previous studies. Conclusions: Our results demonstrated the lack of usefulness in performing routine CT exams to detect asymptomatic liver and lung metastasis in early breast cancer patients. Staging CT might be useful in stage III patients, since 13 (7.5%) patients were upstaged to stage IV by the use of CT. No significant financial relationships to disclose.

scholarly journals A Nomogram for Distinction and Potential Prediction of Liver Metastasis in Breast Cancer Patients

2018 ◽  
Vol 9 (12) ◽  
pp. 2098-2106 ◽  
Author(s):  
Zhenhai Lin ◽  
Shican Yan ◽  
Jieyun Zhang ◽  
Qi Pan
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals Genome‑wide copy number analysis of circulating tumor cells in breast cancer patients with liver metastasis

2020 ◽  
Vol 44 (3) ◽  
pp. 1075-1093 ◽  
Author(s):  
Linglin Zou ◽  
Saber Imani ◽  
Mazaher Maghsoudloo ◽  
Marzieh Shasaltaneh ◽  
Lanyang Gao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Copy Number ◽  
Breast Cancer Patients ◽  
Copy Number Analysis ◽  
Genome Wide

scholarly journals Evaluation of 5′-nucleotide phosphodiesterase isozyme-V as a predictor for liver metastasis in breast cancer patients

Cancer ◽  
1982 ◽  
Vol 50 (2) ◽  
pp. 191-196 ◽  
Author(s):  
K. C. Tsou ◽  
K. W. Lo ◽  
E. F. Rosato ◽  
Anthony Yuk ◽  
H. Enterline ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
Breast Cancer Patients

Association of CA 15-3 and CEA with Liver Metastases in Patients with Breast Cancer

2020 ◽  
Vol 16 (4) ◽  
pp. 332-336
Author(s):  
Akram Yazdani ◽  
Hossein Akbari
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Tumor Size ◽  
Menopausal Status ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Breast Cancer Patients

Objective: The liver is the second most common site of distant metastasis from breast cancer that is usually associated with poor prognosis and low quality of life in breast cancer patients. Therefore, the primary diagnosis of liver metastatic lesions in breast cancer patients is very important. In this study, the ability of biochemical markers CA153, CEA, and ALP to be used for prognostic liver metastasis in women with breast cancer was investigated. Methods: 306 women with breast cancer recorded between 2008 and 2012 were included. Serum concentrations of alkaline phosphatase (ALP), carcinogenicity antigen (CEA), cancer antigen (CA-153), age, menopausal status, histologic type, tumor size and number of cancerous axillary lymph nodes in two groups of breast cancer women with liver metastases and without it were studied. To identify independent liver metastasis prognostic factors, logistic regression method was applied. Results: The independent prognostic factors of liver metastases in women with breast cancer are ALP, CEA, age, menopausal status, number of cancerous axillary lymph nodes and tumor size. Sensitivity and specificity analysis showed that CEA with a cutoff value of 1.1 was the most accurate predictive factor. Conclusion: The increase in the levels of CEA and ALP can be diagnostic markers for liver metastases from breast cancer.

Local treatment of breast in de novo stage IV breast cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11526-e11526
Author(s):  
Peng-Yu Chen ◽  
Skye H Hong-Chun Cheng
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Primary Breast Cancer ◽  
De Novo ◽  
Local Treatment ◽  
Stage Iv ◽  
Breast Cancer Patients ◽  
Stage Iv Breast Cancer

e11526 Background: Stage IV breast cancer is an incurable disease. Systemic therapy is usually the main treatment for these patients. Locoregional therapy, such as surgery or radiotherapy, is controversial. Recent studies suggested locoregional treatments of the primary breast cancer can provide some benefit for these patients. Methods: We conducted a chart review of de novo stage IV breast cancer patients at a cancer center hospital in TAIWAN from 1990 to 2008. A total of 276 patients were reviewed and 268 patients met the inclusion criteria. Tumor characteristics, anti-tumor treatments and survival were analyzed. Results: The median survival of 268 patients was 21.5 months. We divided these patients into two groups. There were 140 patients with less than 21.5 months of survival and 128 patients with more than 21.5 months of survival. In univariate analysis, infiltrating ductal carcinoma (p=0.002), ER-positive (p<0.0001), PR-positive (p<0.0001), and no overexpression of HER2 (p=0.0125) were associated with longer survival. The clinical primary tumor size (p=0.11) and positive axillary lymph node involvement (p=0.61) were not different significantly between two groups. About metastatic site, patients with liver mets (p<0.0001) and lung mets (p=0.025) were associated with shorter survival. Bone mets (p=0.63) was not associated with survival. Patients receiving local treatment of primary tumor, including surgery (p<0.0001) or locoregional radiation (p=0.0034), had longer survival. In multivariate analysis, patients who received surgery of primary breast cancer (HR=0.52, p=0.0006) or received systemic chemotherapy (HR=0.47, p=0.002) had better survival. In subgroup analysis, patients without liver metastasis who received surgery of primary breast cancer had longer overall survival significantly (p<0.0001). In contrast, surgery to the primary breast cancer had no benefit in survival (p=0.91) in patients with liver metastasis. Conclusions: Our institutional experience suggests locoregional treatment for primary breast cancer appear to be beneficial for de novo breast cancer patients, especially those without liver mets.

Sign in / Sign up

Export Citation Format

Share Document